The European Medicines Agency (EMA) said on Thursday its human medicines committee (CHMP) recommended the drug’s use in adults and adolescents from 12 years of age with pneumonia who require oxygen support. In the United States, it could be priced up to $5,080 per course, while Indian generic drugmakers will sell the treatment between 5,000 rupees to 6,000 rupees ($66.13-$79.35). The EMA endorsement, which comes just weeks after a speedy review, means physicians can prescribe the Gilead drug, to be branded Veklury, in Europe once approved by the European Commission, which usually follows CHMP recommendations. …read more
Source:: Yahoo Finance
